Cyclacel Pharmaceuticals, Inc. – NASDAQ:CYCC
Cyclacel Pharmaceuticals stock price today
$7.53
+7.17
+2024.12%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Cyclacel Pharmaceuticals stock price monthly change
-78.48%
month
Cyclacel Pharmaceuticals stock price quarterly change
-78.48%
quarter
Cyclacel Pharmaceuticals stock price yearly change
-87.76%
year
Cyclacel Pharmaceuticals key metrics
Market Cap | 1.99M |
Enterprise value | N/A |
P/E | -0.31 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.14 |
PEG ratio | 0.02 |
EPS | -22.18 |
Revenue | 449K |
EBITDA | -25.82M |
Income | -19.76M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -5751.45% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCyclacel Pharmaceuticals stock price history
Cyclacel Pharmaceuticals stock forecast
Cyclacel Pharmaceuticals financial statements
Average Price Target
$1
Potential downside: -86.71%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 373K | -5.44M | -1460.59% |
|---|---|---|---|
| Sep 2023 | 16K | -6.09M | -38106.25% |
| Dec 2023 | 31K | -5.27M | -17003.23% |
| Mar 2024 | 29K | -2.94M | -10158.62% |
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 1.84% |
|---|---|
| 2020 | 0.71% |
| 2021 | 0.58% |
| 2022 | 3.06% |
| 2023 | 8.85% |
| Jun 2023 | 16442000 | 6.81M | 41.43% |
|---|---|---|---|
| Sep 2023 | 12432000 | 8.08M | 65% |
| Dec 2023 | 8805000 | 8.19M | 93.11% |
| Mar 2024 | 6165000 | 8.37M | 135.78% |
| Jun 2023 | -1.30M | 0 | -51K |
|---|---|---|---|
| Sep 2023 | -4.03M | 4.21M | -50K |
| Dec 2023 | -3.91M | -4.21M | 999K |
| Mar 2024 | -483K | 0 | -79K |
Cyclacel Pharmaceuticals alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
Cyclacel Pharmaceuticals other data
5.55%
-14.40%
of CYCC is owned by hedge funds
10
-17
624.62K
-1.83M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 31824 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MCBARRON PAUL director, officer.. | Common Stock | 3,772 | $3.32 | $12,504 | ||
Purchase | MCBARRON PAUL director, officer.. | Common Stock | 3,772 | $3.32 | $12,504 | ||
Purchase | MCBARRON PAUL director, officer.. | Warrants (right to buy) | 3,772 | $3.19 | $12,033 | ||
Purchase | MCBARRON PAUL director, officer.. | Warrants (right to buy) | 3,772 | $3.19 | $12,033 | ||
Purchase | ROMBOTIS SPIRO GEORGE director, officer.. | Common Stock | 12,140 | $3.32 | $40,244 | ||
Purchase | ROMBOTIS SPIRO GEORGE director, officer.. | Common Stock | 12,140 | $3.32 | $40,244 | ||
Purchase | ROMBOTIS SPIRO GEORGE director, officer.. | Warrants (right to buy) | 12,140 | $3.19 | $38,727 | ||
Purchase | ROMBOTIS SPIRO GEORGE director, officer.. | Warrants (right to buy) | 12,140 | $3.19 | $38,727 | ||
Sale | BARKER SAM L director | Common Stock | 12 | $3.57 | $43 | ||
Purchase | ROMBOTIS SPIRO GEORGE director, officer.. | Common Stock | 4,000 | $4.5 | $18,000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 19 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Cyclacel Pharmaceuticals stock today?
One share of Cyclacel Pharmaceuticals stock can currently be purchased for approximately $7.53.
-
When is Cyclacel Pharmaceuticals's next earnings date?
Unfortunately, Cyclacel Pharmaceuticals's (CYCC) next earnings date is currently unknown.
-
Does Cyclacel Pharmaceuticals pay dividends?
No, Cyclacel Pharmaceuticals does not pay dividends.
-
How much money does Cyclacel Pharmaceuticals make?
Cyclacel Pharmaceuticals has a market capitalization of 1.99M.
-
What is Cyclacel Pharmaceuticals's stock symbol?
Cyclacel Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CYCC".
-
What is Cyclacel Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cyclacel Pharmaceuticals?
Shares of Cyclacel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cyclacel Pharmaceuticals's key executives?
Cyclacel Pharmaceuticals's management team includes the following people:
- Mr. Spiro George Rombotis Pres, Chief Executive Officer & Executive Director(age: 66, pay: $772,640)
- Mr. Paul McBarron Executive Vice President, Chief Financial Officer, Chief Operating Officer, Sec. & Executive Director(age: 64, pay: $391,910)
- Dr. Mark H. Kirschbaum M.D. Senior Vice President & Chief Medical Officer(age: 64, pay: $354,730)
-
How many employees does Cyclacel Pharmaceuticals have?
As Jul 2024, Cyclacel Pharmaceuticals employs 12 workers.
-
When Cyclacel Pharmaceuticals went public?
Cyclacel Pharmaceuticals, Inc. is publicly traded company for more then 21 years since IPO on 16 Mar 2004.
-
What is Cyclacel Pharmaceuticals's official website?
The official website for Cyclacel Pharmaceuticals is cyclacel.com.
-
Where are Cyclacel Pharmaceuticals's headquarters?
Cyclacel Pharmaceuticals is headquartered at 200 Connell Drive, Berkeley Heights, NJ.
-
How can i contact Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals's mailing address is 200 Connell Drive, Berkeley Heights, NJ and company can be reached via phone at +90 85177330.
-
What is Cyclacel Pharmaceuticals stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Cyclacel Pharmaceuticals in the last 12 months, the avarage price target is $1. The average price target represents a -86.71% change from the last price of $7.53.
Cyclacel Pharmaceuticals company profile:
Cyclacel Pharmaceuticals, Inc.
cyclacel.comExchange:
NASDAQ
Full time employees:
12
Industry:
Biotechnology
Sector:
Healthcare
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
200 Connell Drive
Berkeley Heights, NJ 07922
Berkeley Heights, NJ 07922
CIK: 0001130166
ISIN: US23254L8019
CUSIP: 23254L603
